BiotechTube

Cuprimine (penicillamine)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scleroderma

Conditions

Scleroderma

Trial Timeline

— → —

NCT ID
NCT01374282

About Cuprimine (penicillamine)

Cuprimine (penicillamine) is a pre-clinical stage product being developed by Merck for Scleroderma. The current trial status is completed. This product is registered under clinical trial identifier NCT01374282. Target conditions include Scleroderma.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01374282Pre-clinicalCompleted

Competing Products

15 competing products in Scleroderma

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
47
rapcabtagene autoleucel + rituximabNovartisPhase 2
52
STI571NovartisPhase 2
52
Imatinib mesylateNovartisPhase 2
52
imatinib mesylateNovartisPhase 2
52
Mycophenolate mofetilRochePre-clinical
23
Mycophenolate mofetil + Cyclophosphamide + PlaceboRochePhase 2
52
Fludarabine + Cyclophosphamide + ThymoglobulinAmgenPhase 1
32
BMS-986020Bristol Myers SquibbPhase 2
51
dasatinibBristol Myers SquibbPhase 1/2
40
Abatacept + PlaceboBristol Myers SquibbPhase 1/2
40
AVID200Bristol Myers SquibbPhase 1
32
RilonaceptRegeneron PharmaceuticalsPhase 1/2
40
Riociguat + PlaceboBayerPhase 2
49
Riociguat (Adempas, BAY63-2521) + PlaceboBayerPhase 2
49

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85